- Oops!Something went wrong.Please try again later.
Shares of Curevac rose 10% in premarket trading on Friday. Shares of the German biotech have lost 48% this week after the company said a late-stage clinical trial of its COVID-19 vaccine was only 47% effective . But Curevac's chief financial officer, Pierre Kemula, said the company hopes its candidate can still be of use, when a final analysis is done, with that data just two or three weeks away. "We need to look at the data and see, OK, what would be the best value, how we can place this vaccin